Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen-specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









![Figure S5. Antitumor effect by imatinib in mice and molecular targets of imatinib in humans. (A) Total cell numbers of CD8+ and CD4+ T cells in the tumor (top) or the spleen (bottom) of CT26-inoculated BALB/c mice 3 d after the last imatinib treatment (15 d after tumor inoculation) as in Fig. 5 A. (B) The frequency and ratio of T reg cells and CD8+ T cells in Fig. 5 B. (C) Representative staining of Ki-67 and Foxp3 for CellTrace Violet+ T reg cells cultured with or without 10 µM imatinib and 5 U/ml IL-2 for 4 d. CD4+ Foxp3+ (GFP+) T reg cells from Foxp3-IRES-GFP reporter mice were sorted and labeled with CellTrace Violet before the culture (n = 3). Percentages of Ki-67+ cells (left) or mean fluorescence intensity of Foxp3 (right) are indicated in the plots. (D) Gene expression levels of putative targets of imatinib, including ABL1, ABL2, KIT, PDGFRA, LCK, NQO2,and DDR1 in human CD4+ or CD8+ T cells by deepCAGE (Cap Analysis of Gene Expression) database (CNhs 13223 and CNhs 12201). (E) LCK mRNA expressions in naive and effector subsets of CD8+ T, CD4+ T, and T reg cells prepared from PBMCs of healthy donors (n = 6). LCK mRNA levels relative to GAPDH were measured by quantitative real-time PCR. (F) FoxP3 binding near the promoter regions of human PIK3CD (gene encoding phosphatidylinositol-4,5-bisphosphate 3-kinase p110δ [PI3Kδ]) and PTPRC (gene encoding protein tyrosine phosphatase, receptor type C [CD45]) genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011). (G) Signal intensities of pY394-LCK and total LCK protein with or without 10 µM imatinib in Fig. 6 C. AU, arbitrary unit. Error bars indicate means ± SD. Data are pooled from at least two independent experiments. Statistical significance was evaluated by two-sided Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.](https://figures.cochat.ai/paper-figures/5275af670cc04950836f4392cde8e802/tyrosine-kinase-inhibitor-imatinib-augments-tumor-immunity-by-depleting-effector-figure-10.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Tanaka et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 1×
“Analyses of other T cells, in particular CD8+ T cells, revealed that CML patients in CMR possessed significantly higher frequencies and numbers of central memory (CCR7+CD45RA−) and effector memory (CCR7−CD45RA−) CD8+ T cells (Sallusto et al., 1999), with reduction of naive T (CCR7+CD45RA+) cells and terminally differe…”
ResultRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2×
“In accordance with these findings, CD8+ T cells expressing coinhibitory molecules such as PD-1 and LAG-3, but not Tim-3 or CTLA-4, suggestive of an exhausted state (Wherry, 2011), were more abundant in non-CMR patients compared with healthy”
ResultRegulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439 · cited 1×
“…(Fr. III), which appear to be activated conventional T (T conv) cells transiently expressing FoxP3 at a low level, hardly exhibiting suppressive activity, and capable of secreting pro-inflammatory cytokines (Miyara et al., 2009; Saito et al., 2016; Sakaguchi et al., 2010; Sugiyama et al., 2013).”
BackgroundSelf-citationSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372 · cited 1×
“significantly correlated with poor prognosis in various cancers (Bates et al., 2006; Curiel et al., 2004; Sasada et al., 2003; Sato et al., 2005).”
BackgroundSelf-citationMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 2×
“…eT reg cells were physiologically in a more active proliferative state than other T reg cells or T conv cells as shown with freshly isolated eT reg cells or after in vitro culture with IL-2 without exogenous TCR stimulation (Levine et al., 2014; Miyara et al., 2009; Vahl et al., 2014; Fig.”
BackgroundSelf-citation
Cited by
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
“Notably, long-term imatinib-treated CML patients in complete molecular remission with no detectable BCR-ABLmRNA in the blood showed selective depletion of FoxP3+ effector Tregs, whereas those who failed inmolecular remission did not (191).”
BackgroundSelf-citationLi, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
“Mechanistically, because of the much lower expression of Foxp3dependent Lck and ZAP-70 in Tregs compared with other T cells, imatinib inhibition of Lck also reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptosis [147].”
BackgroundTumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Self-citationKoyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 305
“124 The PI3K signaling pathway is also essential for T cell survival and function.”
BackgroundSelf-citationTherapeutic targeting of regulatory T cells in cancer
Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 244
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
“Examples include BCR-ABL kinase inhibitor (2), KRasG12C inhibitor (3), CDK4/6 inhibitors (4), and VEGFR inhibitors (5, 6).”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Kumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 186
“…that targets the oncogenic BCR–ABL1 fusion kinase and is, therefore, used to treat chronic myelogenous leukaemia; however, this agent also inhibits various other kinases, including lymphocyte cell-specific protein tyrosine kinase LCK, which is crucial for TCR-proximal signalling in T cells 167 .”
InfluentialSelf-citationRedín, E., Garmendia, I., Lozano, T., Serrano, D., Senent, Y., Redrado, M., Villalba-Esparza, M., de Andrea, C. E., Expósito, F., Ajona, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001496 · Cited by 90
“To this aim, we studied activation of the LCK, a direct target of dasatinib, whose phosphorylation at Y394 is necessary for TCR signaling initiation.”
BackgroundIsoyama, S., Mori, S., Sugiyama, D., Kojima, Y., Tada, Y., Shitara, K., Hinohara, K., Dan, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002279 · Cited by 90
“14 15–17 Therefore, PI3K δ inhibitors may be good candidates for combination therapy with ICB therapies such as PD-1 blockade.”
InfluentialSelf-citationAptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Camorani, S., Passariello, M., Agnello, L., Esposito, S., Collina, F., Cantile, M., Bonito, M. D., Ulasov, I. V., Fedele, M., Zannetti, A., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01694-9 · Cited by 75
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 77
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Lamplugh, Z. L., Wellhausen, N., June, C. H., & Fan, Y. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01229-3 · Cited by 87
“Another example was provided by a recent retrospective analysis of patients with chronic lymphocytic leukaemia who were treated with imatinib (a ‘dirty’ tyrosine kinase inhibitor with significant off-target effects), which found that imatinib selectively depletes activated T reg cells and increases the ratio between e…”
InfluentialTherapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao, Y. F., Bai, Y., Shen, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992762 · Cited by 57
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy
Negură, I., Tanasa, M. P., & Danciu, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102629 · Cited by 49
Immunometabolism of regulatory T cells in cancer
Saravia, J., & Chi, H. (2025) · Oncogene · doi:10.1038/s41388-025-03458-1 · Cited by 52
“Imatinib treatment promotes a selective loss of activated T reg cells, but not tumor antigen-speci fi c CD8 + T cells, due to the relatively lower levels of tonic LCK signaling in activated T reg cells, thus rendering them more susceptible to TCR deprivation-induced apoptosis [187].”
Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment
Accogli, T., Bruchard, M., & Végran, F. (2021) · Cancers · doi:10.3390/cancers13030373 · Cited by 45
Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias
Swatler, J., Turos-Korgul, L., Kozłowska, E., & Piwocka, K. (2021) · Cancers · doi:10.3390/cancers13061203 · Cited by 44
“Interestingly, regulatory T cells can be directly affected and targeted by imatinib [210,221,222].”
BackgroundMikami, N., Kawakami, R., Sugimoto, A., Arai, M., & Sakaguchi, S. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr6049 · Cited by 43
Self-citationLiang, J., Bi, G., Shan, G., Jin, X., Bian, Y., & Wang, Q. (2022) · Journal of Immunology Research · doi:10.1155/2022/4355386 · Cited by 42
“Two tyrosine kinase inhibitors, imatinib and dasatinib, have been found to inhibit LCK molecules on the surface of T cells as an off-target effect, impairing maintenance and immunosuppressive activity of Tregs by blocking TCR signaling (Figure 1) [84].”
Personalized tumor combination therapy optimization using the single-cell transcriptome
Tang, C., Fu, S., Jin, X., Li, W., Xing, F., Duan, B., Cheng, X., Chen, X., Wang, S., Zhu, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01256-6 · Cited by 36
“…comboSC to a single-cell RNA-seq data-set (SCP1288) with three RCC patients treated with combinatory therapy of ICB and tyrosine kinase inhibitors (TKI) imatinib [91], a drug that inhibits Treg cells and augments immunity in tumor [92], while only P55 showed response to the combinatory therapy.”
MethodRegulation of hematopoietic and leukemia stem cells by regulatory T cells
Riether, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049301 · Cited by 31
“Similarly, Imatinib-treated CML patients in complete molecular remission (CMR) displayed a selective depletion of effector Tregs which was accompanied by an increase in effector/memory CD8 CTLs in contrast to CMR patients who did not reach a complete molecular remission (80).”
ResultRegulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment
Hadjiaggelidou, C., & Katodritou, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194588 · Cited by 30
Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease
Tanaka, A., Maeda, S., Nomura, T., Llamas-Covarrubias, M. A., Tanaka, S., Lin, J., Lim, E. L., Morikawa, H., Kitagawa, Y., Akizuki, S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220386 · Cited by 29
“…the basal expression levels of some TCR signaling molecules, such as Lck, are kept low; upon TCR stimulation, Foxp3 further represses ZAP-70 and some other TCR-proximal signaling molecules by binding to their gene promoter regions (Ohkura et al., 2012; Morikawa et al., 2014; Tanaka et al., 2020).”
Self-citationSignificance of regulatory T cells in cancer immunology and immunotherapy
Sugiyama, D., Hinohara, K., & Nishikawa, H. (2022) · Experimental Dermatology · doi:10.1111/exd.14721 · Cited by 27
Self-citationGawandi, S. J., Desai, V. G., Joshi, S. D., Shingade, S. G., & Pissurlenkar, R. R. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105331 · Cited by 27
Chen, L., Gong, W., Li, M.-H., Zhou, H., Xu, M., Qian, C., Kang, L., Xu, N., Zhou, Y., Qiao, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009072 · Cited by 25
“However, TKI plays an immune modulatory role by selectively depleting Treg cells and increasing the number of effector/memory CD8 T cells to elicit effective immune responses to various cancers.(40) Furthermore, TKI could reduce the differentiation and exhaustion of 4-1BB/CAR T cells during ex vivo expansion, enhancin…”
BackgroundSantiago-Sánchez, G. S., Hodge, J. W., & Fabian, K. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993624 · Cited by 21
Uraki, R., Imai, M., Ito, M., Shime, H., Odanaka, M., Okuda, M., Kawaoka, Y., & Yamazaki, S. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010085 · Cited by 18
Fujioka, Y., Sugiyama, D., Matsumura, I., Minami, Y., Miura, M., Atsuta, Y., Ohtake, S., Kiyoi, H., Miyazaki, Y., Nishikawa, H., et al. (2021) · Cancers · doi:10.3390/cancers13235904 · Cited by 18
“Imatinib concentration was determined according to our previous report [13].”
BackgroundMethodResultInfluentialSelf-citationGeng, C., Chen, F., Zheng, J.-B., Li, T.-Z., Li, T.-Z., Zhang, X., Chen, J., & Chen, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154898 · Cited by 15
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL
Othman, T. A., Logan, A. C., Muffly, L. S., Leonard, J. T., Park, J. H., Shah, B. D., & Aldoss, I. T. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7065 · Cited by 21
Harrington, P., Dillon, R. J., Radia, D. H., Rousselot, P. H., McLornan, D. P., Ong, M., Green, A. C., Verde, A., Hussain, F., Raj, K. K., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282005 · Cited by 14
Barnwal, A., Das, S., & Bhattacharyya, J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00214 · Cited by 13
Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
Damele, L., Ottonello, S., Mingari, M. C., Pietra, G., & Vitale, C. (2020) · Cancers · doi:10.3390/cancers12040774 · Cited by 15
Kagawa, K., Sato, S., Koyama, K., Imakura, T., Murakami, K., Yamashita, Y., Naito, N., Ogawa, H., Kawano, H., & Nishioka, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275987 · Cited by 14
“Furthermore, they also reported that AMG-47a, a Lck inhibitor, selectively reduced the number of effector Tregs [38].”
BackgroundBoutet, M., Nishitani, K., Couturier, N., Erler, P., Zhang, Z., Militello, A. M., de Miranda, M. C., Barbieux, E., Guillen, E., Leavenworth, J. W., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.008 · Cited by 12
Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event
Sanctis, J. B. D., Garmendia, J. V., Duchová, H., Valentini, V., Puskasu, A., Kubíčková, A., & Hajdúch, M. (2024) · Cancers · doi:10.3390/cancers16152630 · Cited by 12
Regulatory T Cells in Tumor Microenvironment: Therapeutic Approaches and Clinical Implications
Sureka, N., & Zaheer, S. (2025) · Cell Biology International · doi:10.1002/cbin.70031 · Cited by 13
“This mechanism highlights imatinib's potential to boost immune ‐ mediated tumor control (Tanaka et al. 2020).”
Saghafian‐Hedengren, S., Sverremark‐Ekström, E., & Nilsson, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.582539 · Cited by 11
Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies
Andreescu, M. (2024) · Cureus · doi:10.7759/cureus.51662 · Cited by 12
“Strong T-cell responses are recorded in patients who receive a very stressful treatment such as hematopoietic cells [62,63].”
BackgroundMatsushita, M. (2021) · Cancers · doi:10.3390/cancers13215435 · Cited by 10
“nases other than ABL1, including KIT, PDGFR, LCK, NQO2, and DDR1 [37].”
BackgroundInfluentialAlfar, R. A., Napoleon, J. V., Shahriar, I., Finnell, R. H., Walchle, C., Johnson, A., & Low, P. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274199 · Cited by 10
“Cyclophosphamide, EZH2 inhibitors, sorafenib, sunitinib, imatinib, and BET inhibitors, as well as antibodies against CD25, FR d , GITR, CCR4, CCR8, NRP-1 and CTLA4 (19 – 24) have been tested for their abilities to reduce Treg immunosuppression.”
BackgroundMethodSmall molecule inhibitors targeting regulatory T cells for cancer treatment
García‐Díaz, N., Wei, Q., & Taskén, K. (2023) · European Journal of Immunology · doi:10.1002/eji.202350448 · Cited by 10
“For instance, Lck levels are lower in Tregs compared with Teffs [35, 36].”
BackgroundWang, D.-Y., Guo, J.-M., Yang, Z., Yuan, G., Li, M., & Li, W. (2020) · medRxiv · doi:10.1101/2020.03.12.20034876 · Cited by 9
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Tsuge, A., Watanabe, S., Kawazoe, A., Togashi, Y., Itahashi, K., Masuda, M., Sai, A., Takei, S., Muraoka, H., Ohkubo, S., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0713 · Cited by 10
Self-citationMishra, A. K., Singh, S., Dayanandan, S., Banerjee, S., Chakraborty, S., Gopal, A. B., Samal, S., Poirah, I., Chakraborty, D., & Bhattacharyya, A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155917 · Cited by 9
Häselbarth, L., Karow, A., Mentz, K., Böttcher, M., Roche-Lancaster, O., Krumbholz, M., Jitschin, R., Mougiakakos, D., & Metzler, M. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03361-8 · Cited by 13
“Three different concentrations for each TKI were chosen in accordance with in vitro data of T cells [7, 8, 14, 15] and with in vivo serum-/plasma concentrations of CML patients [12, 16–20]: Asciminib (MedChemExpress, Monmouth Junction, USA) 1.”
MethodWilson, A., Garmo, L. C., & Podgorski, I. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108274 · Cited by 8
Othman, T. A., Koller, P., Pourhassan, H., Agrawal, V., Ngo, D., Tinajero, J., Ali, H., Cai, J., Mei, M. G., Aribi, A. M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19551 · Cited by 7
“13 Furthermore, one mouse model suggests that TKIs may inhibit differentiation and exhaustion of CAR-T cells.”
Seguro, F. S., Maciel, F. V. R., Santos, F. M., Abdo, A., Pereira, T. D. M., Nardinelli, L., Rocha, V., & Bendit, I. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106516 · Cited by 9
Qin, T., Ma, Y., Dong, C., Wu, W., Feng, Y.-Y., Yang, S., Su, J.-B., Si, X., Wang, X. J., & Shi, D. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133067 · Cited by 6
Wang, C., Chen, Z., Yang, X., Zhang, W., Zhou, J., Zhang, H., Ding, X., Ye, J., Wu, H., Wu, Y., et al. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s349379 · Cited by 7
“Furthermore, patients with chronic myeloid leukemia who achieved complete molecular remission with imatinib treatment showed selective depletion of effector regulatory T cells and an increase in CD8+ T cells.(35) LCK may further stabilize CD28-LCK as a signaling complex by mediating the phosphorylation of CD28 Tyr(207…”
BackgroundWei, Q., Foyn, H., Landskron, J., Wang, S., Rye, I. H., Skånland, S. S., Russnes, H. E. G., Klaveness, J., Rafi, A., & Taskén, K. (2025) · iScience · doi:10.1016/j.isci.2025.111931 · Cited by 5
“16,27,28 Interestingly, MP4 reduced the fraction of eTregs (CD45RA (cid:1) FoxP3 high ) and rTregs (CD45RA + FoxP3 low ) more potently than non-Tregs (CD45RA (cid:1) FoxP3 low ) in stimulated T cells (Figure 3A).”
Asif, M., Amir, M., Hussain, A., Achakzai, N. M., Pushparaj, P. N., & Rasool, M. (2022) · Medicine · doi:10.1097/md.0000000000029660 · Cited by 5
Zhang, H., Liu, Y., Hu, D., & Liu, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844666 · Cited by 5
“Likewise, as tyrosine kinase inhibitor, imatinib can regulate tumor immunity by depleting effector regulatory T cells (46), and it is gradually studied too (47–49).”
BackgroundChen, F., Geng, C., Chou, C., Zheng, J.-B., Yang, Y., Wang, Y., Li, T.-Z., Li, P., Chen, J., & Chen, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154482 · Cited by 5
Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia
Fujioka, Y., Abumiya, M., Ono, T., & Takahashi, N. (2025) · Cancer Medicine · doi:10.1002/cam4.70822 · Cited by 5
Self-citationUreshino, H., Takahashi, N., Ikezoe, T., Kameoka, Y., Kimura, S., Fukushima, N., Ichinohe, T., Takamori, A., Kawaguchi, A., Miura, M., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03830-z · Cited by 6
“Lower Treg numbers are associated with successful achievement of a DMR [24, 27], as well as maintenance of a treatment free remission in CML patients because they activate anti-CML immune responses [28].”
BackgroundSelf-citationSaj, F., Nampoothiri, R. V., Lad, D. P., Jandial, A., Sachdeva, M. U. S., Bose, P. L., Varma, N., Khadwal, A., Prakash, G., & Malhotra, P. (2024) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-024-01843-6 · Cited by 4
“Thus, suppressing Tregs may represent one of the mechanisms by which tyrosine kinase inhibitors (TKIs) exert control over CML [10, 11, 19].”
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
Self-citationWeißenborn, C., von Lenthe, S., Hinz, N., Langwisch, S., Busse, M., Schumacher, A., Zenclussen, A. C., & Fest, S. (2022) · International Journal of Cancer · doi:10.1002/ijc.34262 · Cited by 4
“targeted immunotherapy in patients might be the application of Tregdepleting anti-CCR4 antibody, mogamulizumab, which showed an acceptable safety profile and antitumor activity in an initial human cancer trial.(32) Most recently, specific targeting Treg were accomplished by development of a novel murine Foxp3 antisens…”
BackgroundSabir, S. F., Matti, B. F., & Al-Wattar, W. M. A. (2022) · Immunogenetics · doi:10.1007/s00251-022-01291-4 · Cited by 6
Kothari, N. R., Postwala, H. I., Pandya, A. J., Shah, A. C., Shah, Y. B., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02003-y · Cited by 4
“By targeting other TCR-proximal signaling molecules like ZAP-70, this process of selective depletion of e-Treg cells can be used to develop new immuneenhancing medications that control T reg cells specifically for the treatment of cancer and persistent infections [27].”
BackgroundZiogas, D. C., Mandellos, D., Theocharopoulos, C., Lialios, P., Bouros, S., Ascierto, P. A., & Gogas, H. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.727010 · Cited by 4
“A more recent study noted another immunemediated mechanism of action for imatinib (41).”
BackgroundImatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor
Hirata, A., Sawai, E., Henmi, M., Shibasaki, C., Mizoguchi, Y., Narumi, K., & Aoki, K. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00493 · Cited by 4
KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia
Izumi, K., Shindo, T., Ngo, H. T., Nakayama‐Hosoya, K., Akahane, K., Tamai, M., Nguyen, T. T. T., Kawana‐Tachikawa, A., Inukai, T., & Takaori‐Kondo, A. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100054 · Cited by 5
Wu, S., Wang, Y., Xiao, Z., Zhang, J., He, Z., & Ye, M. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02291-4 · Cited by 3
Management of Chronic Myeloid Leukemia with Sever COVID 19: A Case Report
Ibrahim, R., Chatzis, G., Korayem, M. A., & Mansour, M. K. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.5143 · Cited by 3
“CML patients exhibit selective depletion of effector T-reg cells [8], [9], while TKIs increase the number of natural killer cells (NK), NK-LGL, and T-LGLs cells [10], which play a role in regulating immunity.”
BackgroundPosttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD
Schonewille, P., van Rhenen, A., ten Ham, R. M. T., de Witte, M. A., & Kuball, J. H. E. (2025) · Hematology · doi:10.1182/hematology.2025000747 · Cited by 3
T Cell Receptor Signaling and Immune Tolerance: From Autoimmunity to Cancer Immunity
Tanaka, A., & Sakaguchi, S. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082724-025403 · Cited by 4
Self-citationLiu, W., Xu, W., Liu, W., Liang, R., Tang, S., Luo, X., Liu, C., Liao, Q., Sun, H., Wang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738966 · Cited by 4
Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML
Takahashi, N., Minami, Y., Fujioka, Y., Ohtake, S., Atsuta, Y., Kurata, M., Ono, T., Sato, S., Yano, S., Fujimaki, K., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020915 · Cited by 5
“22 However, the role of TKI-specific immune profiles in sustaining remission after discontinuation remains unclear.”
Self-citationManagement of chronic myelogenous leukemia with COVID-19 and hepatitis B
Tian, Y., Li, W., & Yu, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1217023 · Cited by 2
Establishment of immune suppression by cancer cells in the tumor microenvironment
Nishikawa, H. (2024) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.100.005 · Cited by 3
Self-citationSabir, F. (2021) · Medico-Legal Update · doi:10.37506/mlu.v21i1.2438 · Cited by 2
“Recent study showed that imatinib treated CML patients in complete molecular remission exhibited selective depletion of effector Treg cells and significant increase in effector memory CD8+ T cells while non-complete molecular remission did not (14).”
BackgroundSecond Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
Ureshino, H., Kamachi, K., & Kimura, S. H. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.12.011 · Cited by 3
Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia
Sarlashkar, P., Carr, C. L., & Heberton, M. M. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.08.020 · Cited by 1
“5,6 While this process improves antitumor immunity, it may un-mask underlying autoimmune conditions such as DLE in susceptible individuals.”
BackgroundNishiwaki, S., Sugiura, I., Sato, T., Kobayashi, M., Osaki, M., Sawa, M., Adachi, Y., Okabe, M., Saito, S., Morishita, T., et al. (2023) · eJHaem · doi:10.1002/jha2.677 · Cited by 1
“Moreover, eTreg cells could be selectively inhibited by low doses of imatinib and dasatinib [25].”
BackgroundSelf-citationSeguro, F. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-22072021-151951
Targeting Tumor-Induced Immunosuppression Using Conventional Cancer Therapeutics
Eriksson, E., Lövgren, T., & Loskog, A. (2021) · Medical Research Archives · doi:10.18103/mra.v9i12.2606
“that the TKI imatinib can reduce Tregs as one of the mechanisms behind the positive immune effect using TKIs in cancer.(54) Interestingly, VEGF has a dual role in cancer promoting not only angiogenesis but also”
BackgroundBoutet, M., Nishitani, K., Erler, P., Couturier, N., Zhang, Z., Militello, A. M., de Miranda, M. C., Barbieux, E., Guillen, E., Suzuki, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.02.510540
Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
Öz, Ö., Argon, A., Kebat, T. A., Özdemir, Ö., & Yakan, S. (2023) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_1002_21
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2023) · doi:10.1158/0008-5472.c.6513597.v1
Mikami, N., Kawakami, R., Sugimoto, A., Arai, M., & Sakaguchi, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659621
“…TCR stimulation, S/F-iTregs as well as nTregs down-regulate the expression of Lck and ZAP-70 in a Foxp3-dependent manner, consequently attenuating the intensity of TCR signaling and thereby rendering them resistant to functional exhaustion to be incurred by chronic strong TCR stimulation (62, 63).”
Self-citationTang, C., Fu, S., Jin, X., Li, W., Xing, F., Duan, B., Cheng, X., Chen, X., Wang, S., Zhu, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24715432
Tang, C., Fu, S., Jin, X., Li, W., Xing, F., Duan, B., Cheng, X., Chen, X., Wang, S., Zhu, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24715534
Kwaśnik, P., Stępień, M., Skórka, K., Paziewska, M., Karczmarczyk, A., Pinkosz, M., Cech, P., Zaleska, J., Kiełbus, M., Link-Lenczowska, D., et al. (2025) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.2478/aite-2026-0004
Zhao, Z., Yi, H., Xiao, Y., Li, Z., & Liu, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1692417
Othman, T. A., Roloff, G. W., Miller, K., Zhang, A., Sutherland, K., Faramand, R. G., Hill, L. C., Muhsen, I. N., Jeyakumar, N., Ladha, A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020707
Zhu, Y., Zeng, Y., Lin, W., Zhuang, W., & Qiu, H. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2696796
Tang, B., Li, K., Chen, W., Xiao, J., Duan, Q., & Zhu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857616
Biomaterial-mediated immunomodulation of regulatory T cells in cancer
Hengen, A. C., Kolon, H. H., & Ackun‐Farmmer, M. A. (2026) · Biomaterials Science · doi:10.1039/d6bm00653a
Irradiation-based development of tumor vaccines: Mechanistic insights and translational exploration
Tian, J., Feng, X., Yu, B., Zhang, J., Jing, J., & Jin, X. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105516
Ureshino, H., & Kimura, S. H. (2026) · Cancer Science · doi:10.1111/cas.70532
“Imatinib selectively depletes effector Tregs through off-target inhibition of lymphocyte-specific protein tyrosine kinase (LCK) [62], whereas dasatinib similarly remodels the immune microenvironment by reducing Tregs and promoting NK-cell maturation [63].”
Fujita, M., Ureshino, H., & Kimura, S. H. (2026) · Leukemia · doi:10.1038/s41375-026-03155-2
Metadata
- Authors
- Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., Saito, T., Shinohara, Y., Kameoka, Y., Iwaisako, K., Monma, F., Ohishi, K., Karbach, J., Jäger, E., Sawada, K., Katayama, N., Takahashi, N., & Sakaguchi, S.
- Affiliations
- Immunology Frontier Research Center, The University of Osaka (JP)
- Akita University (JP)
- Kyoto University (JP)
- Mie University (JP)
- Krankenhaus Nordwest (DE)
- Corresponding author
- Sakaguchi, Shimon
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2019-11-08
- Volume
- 217
- Issue
- 2
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7041710
- OpenAlex
- W2989109767
- Cited by
- 96
- References
- 51
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 19 · 2020: 7
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology of Japan (16H06295, 26253030, 23300354, 26290054, 26860331, 17K15723, 17H06162)
- Core Research for Evolutional Science and Technology
- Japan Science and Technology Agency (17gm0410016)
- Japan Agency for Medical Research and Development (18gm0010005, 18cm0106303)
- Ministry of Health, Labor, and Welfare of Japan (H24-Clinical Cancer Research-general-006)
- Cancer Research Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- imatinib, tyrosine kinase inhibitors, regulatory T cells, Foxp3, Lck, ZAP-70, T cell receptor signaling, apoptosis, antitumor immunity, chronic myeloid leukemia, complete molecular remission, CD8+ T cells, melanoma, off-target effects
- MeSH terms
- Imatinib Mesylate, Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Immunity, Mice, Inbred BALB C, Mice, Transgenic, Receptors, Antigen, T-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, SCID, Treatment Outcome, Apoptosis, CD8-Positive T-Lymphocytes, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Cell Line, Tumor, Protein Kinase Inhibitors, T-Lymphocytes, Regulatory, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.